Detalhe da pesquisa
1.
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
J Am Acad Dermatol
; 87(2): 333-342, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35398218
2.
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Clin Transl Sci
; 14(2): 671-682, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33290616
3.
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Lancet Rheumatol
; 3(3): e204-e213, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38279383